Literature DB >> 17643056

High-volume continuous venovenous hemofiltration as an effective therapy for acute management of inborn errors of metabolism in young children.

Yi-Chun Lai1, Hsin-Ping Huang, I-Jung Tsai, Yong-Kwei Tsau.   

Abstract

BACKGROUND/AIM: Renal replacement therapies (RRTs) have been used for the acute management of inborn errors of metabolism. Hemodialysis is the most effective modality. The aim of this article is to demonstrate that high-volume hemofiltration can offer an alternative way to effectively remove small molecules.
METHODS: Eight patients presented with acute neurological deterioration due to ammonia or organic acid accumulation. Different RRTs were applied, including continuous venovenous hemofiltration (CVVH, n = 7), continuous arteriovenous hemofiltration (CAVH, n = 2), continuous venovenous hemodialysis (CVVHD, n = 1), intermittent hemodialysis (HD, n = 1), and peritoneal dialysis (PD, n = 2).
RESULTS: Ammonia 50% reduction time in HD was 1.7 h while in CVVH it was 2-14.5 h. The greater the ultrafiltration flow was, the sooner patients regained consciousness. CAVH, CVVHD or PD was not sufficient enough.
CONCLUSION: CVVH also has a good clearance for organic acid and ammonia if applying high-volume hemofiltration (>35 ml/kg/h). It can be therefore be considered as an alternative therapy if infant HD is not available. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643056     DOI: 10.1159/000106102

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism.

Authors:  I-Jung Tsai; Wuh-Liang Hwu; Shu-Chien Huang; Ni-Chung Lee; En-Ting Wu; Yin-Hsiu Chien; Yong-Kwei Tsau
Journal:  Pediatr Nephrol       Date:  2013-09-08       Impact factor: 3.714

2.  Short-term survival of hyperammonemic neonates treated with dialysis.

Authors:  Stefano Picca; Carlo Dionisi-Vici; Andrea Bartuli; Tommaso De Palo; Francesco Papadia; Giovanni Montini; Marco Materassi; Maria Alice Donati; Enrico Verrina; Maria Cristina Schiaffino; Carmine Pecoraro; Emilia Iaccarino; Enrico Vidal; Alberto Burlina; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2014-09-04       Impact factor: 3.714

3.  Continuous Renal Replacement Therapy for Treatment of Severe Attacks of Inborn Errors of Metabolism.

Authors:  Ayse Filiz Yetimakman; Selman Kesici; Murat Tanyildiz; Benan Bayrakci
Journal:  J Pediatr Intensive Care       Date:  2019-03-27

4.  Continuous hemofiltration in the control of neonatal hyperammonemia: a 10-year experience.

Authors:  Claire Westrope; Kevin Morris; David Burford; Gavin Morrison
Journal:  Pediatr Nephrol       Date:  2010-05-22       Impact factor: 3.714

5.  Multisite Retrospective Review of Outcomes in Renal Replacement Therapy for Neonates with Inborn Errors of Metabolism.

Authors:  Elizabeth G Ames; Corey Powell; Rachel M Engen; Donald J Weaver; Asif Mansuri; Michelle N Rheault; Keia Sanderson; Uta Lichter-Konecki; Ankana Daga; Lindsay C Burrage; Ayesha Ahmad; Scott E Wenderfer; Kera E Luckritz
Journal:  J Pediatr       Date:  2022-03-28       Impact factor: 6.314

Review 6.  Pediatric renal replacement therapy in the intensive care unit.

Authors:  Brian C Bridges; David J Askenazi; Jessimene Smith; Stuart L Goldstein
Journal:  Blood Purif       Date:  2012-10-24       Impact factor: 2.614

Review 7.  The Role of RRT in Hyperammonemic Patients.

Authors:  Shruti Gupta; Andrew Z Fenves; Robert Hootkins
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

8.  Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.

Authors:  Paula Sánchez-Pintos; Silvia Meavilla; María Goretti López-Ramos; Ángeles García-Cazorla; Maria L Couce
Journal:  Front Pediatr       Date:  2022-08-15       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.